<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950416</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-14</org_study_id>
    <nct_id>NCT01950416</nct_id>
  </id_info>
  <brief_title>Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis</brief_title>
  <official_title>Pharmacodynamic Assessment of Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Exhibiting High Platelet Reactivity Post Fibrinolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-center, prospective, randomized, single-blind, investigator initiated,
      pharmacodynamic study of parallel design, carried out in 2 PCI-capable cardiology centers
      (Patras University Hospital and Konstantopoulio General Hospital of Athens).

      Patients with ST elevation myocardial infarction, having undergone fibrinolysis in the
      previous 3 to 48 hours, who present high residual PR (defined as PRU ≥208 ) on admission, pre
      coronary angiography, will be randomized after written informed consent, in a 1:1 ratio to
      either:

      Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6
      hours post LD, until discharge.

      Or

      Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD)
      starting 12±6 hours post LD, until discharge.

      Platelet reactivity assessment will be performed at randomization (Hour 0) and at 2, 24 hours
      after randomization, as well as pre-discharge, using the VerifyNow assay, in platelet
      reactivity units (PRU).

      Documentation of major adverse cardiac events (death, myocardial infarction, stroke, ischemia
      driven revascularization procedure with PCI or CABG) and bleeding (according to BARC
      criteria) will be performed until patient's discharge.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity at 2 hours post randomization between the 2 treatment arms</measure>
    <time_frame>2 hours</time_frame>
    <description>Platelet reactivity at 2 hours post randomization between the 2 treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity at 24 hours post randomization between the 2 treatment arms.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity pre-discharge between the 2 treatment arms</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity (HPR) rate (≥208 PRU) at 2 hours post randomization</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity (HPR) rate (≥208 PRU) at 24 hours post randomization</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High on treatment platelet reactivity (HPR) rates (≥208 PRU) pre discharge</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Fibrinolysis</condition>
  <condition>P2Y12 Inhibitor</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</intervention_name>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 600mg loading dose and 150mg maintenance dose</intervention_name>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-85 years old

          2. Patients with STEMI, having undergone fibrinolytic therapy in the previous 3 to 48
             hours

          3. Presenting HPR (≥208 PRU) post 300mg clopidogrel loading dose ( assessment immediately
             before coronary angiography)

          4. Informed consent obtained in writing

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Inability to give informed consent

          -  Cardiogenic shock

          -  Major periprocedural complications (death, stent thrombosis, vessel perforation,
             arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous
             antiarrhythmic agents, respiratory failure requiring intubation, vascular injury
             (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood
             transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding)

          -  Known hypersensitivity to ticagrelor or clopidogrel

          -  History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal
             bleeding within the previous 3 months.

          -  Other bleeding diathesis, or considered by investigator to be at high risk for
             bleeding

          -  Any previous history of stroke, intracranial hemorrhage or disease (neoplasm,
             arteriovenous malformation, aneurysm).

          -  Thombocytopenia (&lt;100.000 / μL) at randomization

          -  Anaemia (Hct &lt;30%) at randomization

          -  Polycytaemia (Hct &gt; 52%) at randomization

          -  Periprocedural IIb/IIIa inhibitors administration

          -  Per os anticoagulants

          -  Recent (&lt; 6 weeks) major surgery or trauma, including GABG.

          -  Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)
             or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of
             the study.

          -  Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole,
             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,
             saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A
             substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A
             inducers (rifampin /rifampicin, phenytoin, carbamazepine).

          -  Increased risk of bradycardiac events.

          -  Dialysis required.

          -  Severe uncontrolled chronic obstructive pulmonary disease

          -  Known severe hepatic impairement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Konstantopoulio General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>14233</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ST elevation myocardial infarction</keyword>
  <keyword>Fibrinolysis</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Platelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

